System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Francesco Giorgino is an expert in Endocrinology at University of Bari Aldo Moro (Italy). As of October 2026, ScienceLeadR ranks Francesco Giorgino in the top 1% of experts worldwide for Diabetes Mellitus, Glucose Metabolism Disorders and Overweight. Francesco Giorgino has authored 487 publications, the most recent in 2026, and is an investigator in 36 clinical trials, 10 of them ongoing. SLR score: 1,990 (community average: 125). How the SLR is computed.

LeadR Profile

Francesco Giorgino University of Bari Aldo Moro Italy
1 990 ScienceLeadR Reputation 1990

Unlock

Register Login
Network Map

Endocrinology

Subspecialties: Cardiology - Biochemistry - Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1992 - 2026
Source: PubMed

University of Bari Aldo Moro

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 487

Citations

Citations: 20 827 1st author: 47 Last author: 119 Unique author: 2

Main journals

J Endocrinol Invest 36
Diabetes Obes Metab 31
Diabetes 23
Diabetes Care 22
Cardiovasc Diabetol 15

Best Journals

N Engl J Med 3
JAMA 2
Lancet 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Insulin pens and the digital ecosystem.
PMID 42776165 — diabetes mellitus, insulin, ecosystem, therapeutics		Diabetologia20260
Orforglipron for Type 2 Diabetes and Pancreatic Risk Assessment-Reply.
PMID 42931748 — diabetes mellitus, risk assessment, diabetes mellitus, type 2		JAMA Top journal20260
Diagnosis and management of polycystic ovary syndrome/polyendocrine metabolic ovarian syndrome: unmet needs and areas of clinical confidence among European endocrinologists.
PMID 42905305 — endocrinology, cross-sectional studies, life style, ovary, endocrinologists, diagnosis, polycystic ovary syndrome, therapeutics, steroids		J Endocrinol Invest20260
Incretin-Based Therapy in Patients with Malignancy and Obesity or Type 2 Diabetes. An Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF), and Italian Society of Obesity (SIO) Position Paper.
PMID 42823599 — diabetes mellitus, endocrinology, neoplasms, pharmacology, obesity, incretins, therapeutics, medical oncology, drug interactions, diabetes mellitus, type 2		Obes Rev20260
Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
PMID 42825923 — diabetes mellitus, glucagon-like peptide 1, therapeutics, diabetes mellitus, type 2		Diabetologia20261

Clinical Studies 36

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 15
N/A 14
Phase 4 6
Phase 2 1

By status:

Completed 22
Recruiting 6
Not yet recruiting 3
Unknown 3
Active not recruiting 2

By type:

Interventional 25
Observational 11

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 3
multicentric5to9 2
multicentricup10 25

Main Topics

Cohort/Consortium Investigators 8

Ongoing Clinical Trials

10 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase III Study to Investigate the Risk of Incident Heart Failure and Cardiovascular Death with Baxdrostat in Combination with Dapagliflozin in Participants with Increased Risk of Developing Heart Failure
2024-514506-32-00 — heart failure, heart		Phase 3Not yet recruiting2025
A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes
2025-523104-71-00 — diabetes mellitus, safety, obesity, overweight, diabetes mellitus, type 2		Phase 3Recruiting2026
A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight and type 2 diabetes
2025-523106-32-00 — diabetes mellitus, safety, obesity, overweight, diabetes mellitus, type 2		Phase 3Not yet recruiting2026
Searching simple biomarkers to phenotype type 2 diabetic patients and personalize their treatment
2024-516542-19-00 — diabetes mellitus, insulin, phenotype, biomarkers, therapeutics, diabetes mellitus, type 2		Phase 4Recruiting2025
Extreme Phenotypes to Identify Susceptibility of Patients Living With Type 2 to Diabetes Related Complications
NCT07250607 — diabetes mellitus, cardiovascular diseases, phenotype, hyperglycemia, biomarkers, diabetes complications, diabetes mellitus, type 2		N/AActive not recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS